NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
»20/10/2009 [Industry news]
1st domestic liposomal peg-doxorubicin enters market

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical announced October 18 that it has introduced its cancer treatment injection, pegylated doxorubicin HCl liposome injection, to the market, according to www.caixun.com.

 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical announced October 18 that it has introduced its cancer treatment injection, pegylated doxorubicin HCl liposome injection, to the market, according to www.caixun.com. It is the first domestic version of the liposome-encapsulated drug to be marketed in China (Note: there are other domestic registrations for doxorubicin, but not in its liposome-encapsulated form). The liposomal formulation of the drug is marketed in the US as Doxil by Johnson & Johnson/Alza, and as Caelyx by Schering-Plough in China. According to Haibo Wang, general manager of the company, the price of its domestic version is at least one-third lower than that of multinational versions.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.